
Generic Drugs Industry Research Report 2024
Description
Generic Drugs Industry Research Report 2024
Summary
A generic drug is a pharmaceutical drug that is equivalent to a brand-name product in dosage, strength, route of administration, quality, performance, and intended use. The term may also refer to any drug marketed under its chemical name without advertising, or to the chemical makeup of a drug rather than the brand name under which the drug is sold.
According to APO Research, The global Generic Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of xx% during the forecast period 2024-2030.
North American market for Generic Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Generic Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Generic Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global companies of Generic Drugs include Teva, Novartis - Sandoz, Mylan, Sun Pharmaceutical, Aspen, Fresenius Kabi, Pfizer (Hospira), Sanofi and Aurobindo, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Generic Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Generic Drugs.
The Generic Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Generic Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
Teva
Novartis - Sandoz
Mylan
Sun Pharmaceutical
Aspen
Fresenius Kabi
Pfizer (Hospira)
Sanofi
Aurobindo
Lupin
Dr. Reddy's
Apotex
Cipla
ENDO (Par Pharmaceutical)
Stada Arzneimittel
Krka Group
Nichi-Iko Pharmaceutical
Valeant
Zydus Cadila
Hikma
Pharmaniaga Berhad
Hovid Berhad
Duopharma Biotech
Kotra Pharma
HOE Pharmaceutical
Y.S.P. Industries
Generic Drugs segment by Type
Prescription
Non-Prescription Drugs
Generic Drugs Segment by Application
Hospital
Clinic
Others
Generic Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Generic Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Generic Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Generic Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Generic Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
Table of Contents
146 Pages
- 1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
- 2 Market Overview
- 2.1 Product Definition
- 2.2 Generic Drugs by Type
- 2.2.1 Market Value Comparison by Type (2019 VS 2023 VS 2030)
- 2.2.2 Prescription
- 2.2.3 Non-Prescription Drugs
- 2.3 Generic Drugs by Application
- 2.3.1 Market Value Comparison by Application (2019 VS 2023 VS 2030)
- 2.3.2 Hospital
- 2.3.3 Clinic
- 2.3.4 Others
- 2.4 Assumptions and Limitations
- 3 Generic Drugs Breakdown Data by Type
- 3.1 Global Generic Drugs Historic Market Size by Type (2019-2024)
- 3.2 Global Generic Drugs Forecasted Market Size by Type (2025-2030)
- 4 Generic Drugs Breakdown Data by Application
- 4.1 Global Generic Drugs Historic Market Size by Application (2019-2024)
- 4.2 Global Generic Drugs Forecasted Market Size by Application (2019-2024)
- 5 Global Growth Trends
- 5.1 Global Generic Drugs Market Perspective (2019-2030)
- 5.2 Global Generic Drugs Growth Trends by Region
- 5.2.1 Global Generic Drugs Market Size by Region: 2019 VS 2023 VS 2030
- 5.2.2 Generic Drugs Historic Market Size by Region (2019-2024)
- 5.2.3 Generic Drugs Forecasted Market Size by Region (2025-2030)
- 5.3 Generic Drugs Market Dynamics
- 5.3.1 Generic Drugs Industry Trends
- 5.3.2 Generic Drugs Market Drivers
- 5.3.3 Generic Drugs Market Challenges
- 5.3.4 Generic Drugs Market Restraints
- 6 Market Competitive Landscape by Players
- 6.1 Global Top Generic Drugs Players by Revenue
- 6.1.1 Global Top Generic Drugs Players by Revenue (2019-2024)
- 6.1.2 Global Generic Drugs Revenue Market Share by Players (2019-2024)
- 6.2 Global Generic Drugs Industry Players Ranking, 2022 VS 2023 VS 2024
- 6.3 Global Key Players of Generic Drugs Head office and Area Served
- 6.4 Global Generic Drugs Players, Product Type & Application
- 6.5 Global Generic Drugs Players, Date of Enter into This Industry
- 6.6 Global Generic Drugs Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
- 7 North America
- 7.1 North America Generic Drugs Market Size (2019-2030)
- 7.2 North America Generic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
- 7.3 North America Generic Drugs Market Size by Country (2019-2024)
- 7.4 North America Generic Drugs Market Size by Country (2025-2030)
- 7.5 United States
- 7.6 Canada
- 8 Europe
- 8.1 Europe Generic Drugs Market Size (2019-2030)
- 8.2 Europe Generic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
- 8.3 Europe Generic Drugs Market Size by Country (2019-2024)
- 8.4 Europe Generic Drugs Market Size by Country (2025-2030)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Russia
- 8.10 Nordic Countries
- 9 Asia-Pacific
- 9.1 Asia-Pacific Generic Drugs Market Size (2019-2030)
- 9.2 Asia-Pacific Generic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
- 9.3 Asia-Pacific Generic Drugs Market Size by Country (2019-2024)
- 9.4 Asia-Pacific Generic Drugs Market Size by Country (2025-2030)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 Southeast Asia
- 9.9 India
- 9.10 Australia
- 10 Latin America
- 10.1 Latin America Generic Drugs Market Size (2019-2030)
- 10.2 Latin America Generic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
- 10.3 Latin America Generic Drugs Market Size by Country (2019-2024)
- 10.4 Latin America Generic Drugs Market Size by Country (2025-2030)
- 10.5 Mexico
- 10.6 Brazil
- 11 Middle East & Africa
- 11.1 Middle East & Africa Generic Drugs Market Size (2019-2030)
- 11.2 Middle East & Africa Generic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
- 11.3 Middle East & Africa Generic Drugs Market Size by Country (2019-2024)
- 11.4 Middle East & Africa Generic Drugs Market Size by Country (2025-2030)
- 11.5 Turkey
- 11.6 Saudi Arabia
- 11.7 UAE
- 12 Players Profiled
- 12.1 Teva
- 12.1.1 Teva Company Information
- 12.1.2 Teva Business Overview
- 12.1.3 Teva Revenue in Generic Drugs Business (2019-2024)
- 12.1.4 Teva Generic Drugs Product Portfolio
- 12.1.5 Teva Recent Developments
- 12.2 Novartis - Sandoz
- 12.2.1 Novartis - Sandoz Company Information
- 12.2.2 Novartis - Sandoz Business Overview
- 12.2.3 Novartis - Sandoz Revenue in Generic Drugs Business (2019-2024)
- 12.2.4 Novartis - Sandoz Generic Drugs Product Portfolio
- 12.2.5 Novartis - Sandoz Recent Developments
- 12.3 Mylan
- 12.3.1 Mylan Company Information
- 12.3.2 Mylan Business Overview
- 12.3.3 Mylan Revenue in Generic Drugs Business (2019-2024)
- 12.3.4 Mylan Generic Drugs Product Portfolio
- 12.3.5 Mylan Recent Developments
- 12.4 Sun Pharmaceutical
- 12.4.1 Sun Pharmaceutical Company Information
- 12.4.2 Sun Pharmaceutical Business Overview
- 12.4.3 Sun Pharmaceutical Revenue in Generic Drugs Business (2019-2024)
- 12.4.4 Sun Pharmaceutical Generic Drugs Product Portfolio
- 12.4.5 Sun Pharmaceutical Recent Developments
- 12.5 Aspen
- 12.5.1 Aspen Company Information
- 12.5.2 Aspen Business Overview
- 12.5.3 Aspen Revenue in Generic Drugs Business (2019-2024)
- 12.5.4 Aspen Generic Drugs Product Portfolio
- 12.5.5 Aspen Recent Developments
- 12.6 Fresenius Kabi
- 12.6.1 Fresenius Kabi Company Information
- 12.6.2 Fresenius Kabi Business Overview
- 12.6.3 Fresenius Kabi Revenue in Generic Drugs Business (2019-2024)
- 12.6.4 Fresenius Kabi Generic Drugs Product Portfolio
- 12.6.5 Fresenius Kabi Recent Developments
- 12.7 Pfizer (Hospira)
- 12.7.1 Pfizer (Hospira) Company Information
- 12.7.2 Pfizer (Hospira) Business Overview
- 12.7.3 Pfizer (Hospira) Revenue in Generic Drugs Business (2019-2024)
- 12.7.4 Pfizer (Hospira) Generic Drugs Product Portfolio
- 12.7.5 Pfizer (Hospira) Recent Developments
- 12.8 Sanofi
- 12.8.1 Sanofi Company Information
- 12.8.2 Sanofi Business Overview
- 12.8.3 Sanofi Revenue in Generic Drugs Business (2019-2024)
- 12.8.4 Sanofi Generic Drugs Product Portfolio
- 12.8.5 Sanofi Recent Developments
- 12.9 Aurobindo
- 12.9.1 Aurobindo Company Information
- 12.9.2 Aurobindo Business Overview
- 12.9.3 Aurobindo Revenue in Generic Drugs Business (2019-2024)
- 12.9.4 Aurobindo Generic Drugs Product Portfolio
- 12.9.5 Aurobindo Recent Developments
- 12.10 Lupin
- 12.10.1 Lupin Company Information
- 12.10.2 Lupin Business Overview
- 12.10.3 Lupin Revenue in Generic Drugs Business (2019-2024)
- 12.10.4 Lupin Generic Drugs Product Portfolio
- 12.10.5 Lupin Recent Developments
- 12.11 Dr. Reddy's
- 12.11.1 Dr. Reddy's Company Information
- 12.11.2 Dr. Reddy's Business Overview
- 12.11.3 Dr. Reddy's Revenue in Generic Drugs Business (2019-2024)
- 12.11.4 Dr. Reddy's Generic Drugs Product Portfolio
- 12.11.5 Dr. Reddy's Recent Developments
- 12.12 Apotex
- 12.12.1 Apotex Company Information
- 12.12.2 Apotex Business Overview
- 12.12.3 Apotex Revenue in Generic Drugs Business (2019-2024)
- 12.12.4 Apotex Generic Drugs Product Portfolio
- 12.12.5 Apotex Recent Developments
- 12.13 Cipla
- 12.13.1 Cipla Company Information
- 12.13.2 Cipla Business Overview
- 12.13.3 Cipla Revenue in Generic Drugs Business (2019-2024)
- 12.13.4 Cipla Generic Drugs Product Portfolio
- 12.13.5 Cipla Recent Developments
- 12.14 ENDO (Par Pharmaceutical)
- 12.14.1 ENDO (Par Pharmaceutical) Company Information
- 12.14.2 ENDO (Par Pharmaceutical) Business Overview
- 12.14.3 ENDO (Par Pharmaceutical) Revenue in Generic Drugs Business (2019-2024)
- 12.14.4 ENDO (Par Pharmaceutical) Generic Drugs Product Portfolio
- 12.14.5 ENDO (Par Pharmaceutical) Recent Developments
- 12.15 Stada Arzneimittel
- 12.15.1 Stada Arzneimittel Company Information
- 12.15.2 Stada Arzneimittel Business Overview
- 12.15.3 Stada Arzneimittel Revenue in Generic Drugs Business (2019-2024)
- 12.15.4 Stada Arzneimittel Generic Drugs Product Portfolio
- 12.15.5 Stada Arzneimittel Recent Developments
- 12.16 Krka Group
- 12.16.1 Krka Group Company Information
- 12.16.2 Krka Group Business Overview
- 12.16.3 Krka Group Revenue in Generic Drugs Business (2019-2024)
- 12.16.4 Krka Group Generic Drugs Product Portfolio
- 12.16.5 Krka Group Recent Developments
- 12.17 Nichi-Iko Pharmaceutical
- 12.17.1 Nichi-Iko Pharmaceutical Company Information
- 12.17.2 Nichi-Iko Pharmaceutical Business Overview
- 12.17.3 Nichi-Iko Pharmaceutical Revenue in Generic Drugs Business (2019-2024)
- 12.17.4 Nichi-Iko Pharmaceutical Generic Drugs Product Portfolio
- 12.17.5 Nichi-Iko Pharmaceutical Recent Developments
- 12.18 Valeant
- 12.18.1 Valeant Company Information
- 12.18.2 Valeant Business Overview
- 12.18.3 Valeant Revenue in Generic Drugs Business (2019-2024)
- 12.18.4 Valeant Generic Drugs Product Portfolio
- 12.18.5 Valeant Recent Developments
- 12.19 Zydus Cadila
- 12.19.1 Zydus Cadila Company Information
- 12.19.2 Zydus Cadila Business Overview
- 12.19.3 Zydus Cadila Revenue in Generic Drugs Business (2019-2024)
- 12.19.4 Zydus Cadila Generic Drugs Product Portfolio
- 12.19.5 Zydus Cadila Recent Developments
- 12.20 Hikma
- 12.20.1 Hikma Company Information
- 12.20.2 Hikma Business Overview
- 12.20.3 Hikma Revenue in Generic Drugs Business (2019-2024)
- 12.20.4 Hikma Generic Drugs Product Portfolio
- 12.20.5 Hikma Recent Developments
- 12.21 Pharmaniaga Berhad
- 12.21.1 Pharmaniaga Berhad Company Information
- 12.21.2 Pharmaniaga Berhad Business Overview
- 12.21.3 Pharmaniaga Berhad Revenue in Generic Drugs Business (2019-2024)
- 12.21.4 Pharmaniaga Berhad Generic Drugs Product Portfolio
- 12.21.5 Pharmaniaga Berhad Recent Developments
- 12.22 Hovid Berhad
- 12.22.1 Hovid Berhad Company Information
- 12.22.2 Hovid Berhad Business Overview
- 12.22.3 Hovid Berhad Revenue in Generic Drugs Business (2019-2024)
- 12.22.4 Hovid Berhad Generic Drugs Product Portfolio
- 12.22.5 Hovid Berhad Recent Developments
- 12.23 Duopharma Biotech
- 12.23.1 Duopharma Biotech Company Information
- 12.23.2 Duopharma Biotech Business Overview
- 12.23.3 Duopharma Biotech Revenue in Generic Drugs Business (2019-2024)
- 12.23.4 Duopharma Biotech Generic Drugs Product Portfolio
- 12.23.5 Duopharma Biotech Recent Developments
- 12.24 Kotra Pharma
- 12.24.1 Kotra Pharma Company Information
- 12.24.2 Kotra Pharma Business Overview
- 12.24.3 Kotra Pharma Revenue in Generic Drugs Business (2019-2024)
- 12.24.4 Kotra Pharma Generic Drugs Product Portfolio
- 12.24.5 Kotra Pharma Recent Developments
- 12.25 HOE Pharmaceutical
- 12.25.1 HOE Pharmaceutical Company Information
- 12.25.2 HOE Pharmaceutical Business Overview
- 12.25.3 HOE Pharmaceutical Revenue in Generic Drugs Business (2019-2024)
- 12.25.4 HOE Pharmaceutical Generic Drugs Product Portfolio
- 12.25.5 HOE Pharmaceutical Recent Developments
- 12.26 Y.S.P. Industries
- 12.26.1 Y.S.P. Industries Company Information
- 12.26.2 Y.S.P. Industries Business Overview
- 12.26.3 Y.S.P. Industries Revenue in Generic Drugs Business (2019-2024)
- 12.26.4 Y.S.P. Industries Generic Drugs Product Portfolio
- 12.26.5 Y.S.P. Industries Recent Developments
- 13 Report Conclusion
- 14 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.